A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease.

@article{Moe2010ART,
  title={A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease.},
  author={Sharon M. Moe and Akber Saifullah and R Laclair and Sohail A Usman and Zhangsheng Yu},
  journal={Clinical journal of the American Society of Nephrology : CJASN},
  year={2010},
  volume={5 2},
  pages={299-306}
}
BACKGROUND AND OBJECTIVES The optimal treatment of secondary hyperparathyroidism in chronic kidney disease (CKD) is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS We conducted a randomized, blinded, 3-month trial in vitamin D-deficient CKD stage 3 and 4 patients with parathyroid hormone (PTH) values above the Kidney Disease Outcomes Quality Initiative target, comparing cholecalciferol (4000 IU/d x 1 month, then 2000 IU/d; n = 22) to doxercalciferol (1 microg/d; n = 25). RESULTS… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

Similar Papers

Loading similar papers…